<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03160638</url>
  </required_header>
  <id_info>
    <org_study_id>AZT_DSTB_BB</org_study_id>
    <nct_id>NCT03160638</nct_id>
  </id_info>
  <brief_title>Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis</brief_title>
  <official_title>A Prospective, Randomized Pilot Study of the Immunomodulatory Effects of Azithromycin in Adults With Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      Treatment in tuberculosis (TB) is focused on eradication of the bacterial infection, however,
      after treatment approximately half of patients are left with a significant and permanent
      respiratory impairment. Adjunctive host-directed therapies are being investigated to modulate
      host immune responses to target mycobacterium tuberculosis (Mtb) infection and/or reduce
      excessive inflammation, prevent pathological tissue damage, preserve lung function and
      enhance effectiveness of standard drug therapy, while nonetheless eliminating Mtb. Macrolide
      antibiotics have previously been used in the treatment of multidrug-resistant TB. In addition
      to their antibiotic effects, macrolides have also been recognized to induce anti-inflammatory
      and immunomodulatory effects in other lung diseases.

      Objective:

      To investigate the immunomodulatory effects of azithromycin in tuberculosis patients
      receiving standard therapy (isoniazid, rifampicin, pyrazinamide, ethambutol (HRZE))

      Study design:

      A prospective, randomized open label intervention trial to investigate the immunomodulatory
      effects of azithromycin

      Study population: 24

      Intervention: azithromycin 250 mg once daily or standard of care (control)

      Main study parameters/endpoints:

        1. To assess whether azithromycin enhances resolution of systemic inflammation in patients
           with drug susceptible pulmonary TB receiving standard treatment.

        2. To assess whether azithromycin on top of standard treatment in patients with drug
           susceptible pulmonary TB reduces airway inflammation and reduces tissue degradation and
           remodeling

        3. To investigate whether these effects are associated within shortening of the time to
           sputum conversion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic inflammation</measure>
    <time_frame>Before randomization, day 7 and day 28</time_frame>
    <description>Changes in total &amp; differential white blood cell counts markers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic inflammation</measure>
    <time_frame>Before randomization, day 7 and day 28</time_frame>
    <description>Changes in serum inflammatory markers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary inflammation</measure>
    <time_frame>Before randomization and day 28</time_frame>
    <description>Changes in total and differential sputum inflammatory cell counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary inflammation</measure>
    <time_frame>Before randomization and day 28</time_frame>
    <description>Changes in cytokine levels in sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary tissue degradation</measure>
    <time_frame>Before randomization and day 28</time_frame>
    <description>Changes in markers of tissue degradation in sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary tissue degradation</measure>
    <time_frame>Before randomization, day 7 and day 28</time_frame>
    <description>Changes in markers of tissue degradation in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary tissue remodeling</measure>
    <time_frame>Before randomization and day 28</time_frame>
    <description>Changes in markers of tissue remodeling in sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary tissue remodeling</measure>
    <time_frame>Before randomization, day 7 and day 28</time_frame>
    <description>Changes in markers of tissue remodeling in serum</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of HRZE treatment outcomes</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Time to sputum conversion</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of HRZE treatment outcomes</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Drug exposure of HRZE in relation to minimal inhibitory concentration (MIC) of Mtb for HRZE</description>
  </other_outcome>
  <other_outcome>
    <measure>Drug exposure of azithromycin</measure>
    <time_frame>Day 7</time_frame>
    <description>AUC0-24h of azithromycin in TB</description>
  </other_outcome>
  <other_outcome>
    <measure>Drug exposure of azithromycin</measure>
    <time_frame>Day 7</time_frame>
    <description>Metabolic clearance (CLm) of azithromycin in TB</description>
  </other_outcome>
  <other_outcome>
    <measure>Drug exposure of azithromycin</measure>
    <time_frame>Day 7</time_frame>
    <description>Volume of distribution (V) of azithromycin in TB</description>
  </other_outcome>
  <other_outcome>
    <measure>Drug exposure of azithromycin</measure>
    <time_frame>Day 7</time_frame>
    <description>Elimination half-life (T1/2) of azithromycin in TB</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Azithromycin arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will be treated with azithromycin 250 mg once daily on top of standard HRZE treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this arm will receive no additional treatment on top of standard HRZE treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin 250 mg</intervention_name>
    <description>Patients will be treated with azithromycin 250 mg once daily for 28 days. An azithromycin loading dose of 500 mg (two tablets of 250 mg) will be administered on day 1</description>
    <arm_group_label>Azithromycin arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of drug sensitive pulmonary tuberculosis (molecular test;
             identification Mtb complex; absence of resistance genes such as rpob, inha, katg)

          -  Written informed consent

        Exclusion Criteria:

          -  Patient reported previous history of treatment for tuberculosis

          -  Patients younger than 18 years

          -  Pregnancy or breast feeding

          -  Patients with hypersensitivity to macrolide antibiotics

          -  Treatment with any macrolide in the previous month

          -  Treatment with any tetracycline in the previous month

          -  Treatment with any inhaled or oral corticosteroid in the previous month

          -  Concomitant treatment with analgesic (NSAIDs)/immunosuppressant drugs (except
             paracetamol).

          -  Treatment with digoxin

          -  Patients with gastrointestinal complaints, like diarrhea and vomiting (≥grade 2,
             observed)

          -  Other known respiratory diseases, including bronchiectasis, pulmonary fibrosis,
             pulmonary vascular disease or lung cancer

          -  HIV-1 infection or AIDS

          -  Impaired liver function (Child-Pugh score C)

          -  Patients with a known QTc ≥500 ms. An electrocardiogram (ECG) will be recorded.

          -  Inability to spontaneously produce sputum upon diagnosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bart Dekkers, PharmD, PhD</last_name>
    <phone>+31506314070</phone>
    <email>b.g.j.dekkers@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan-Willem Alffenaar, PharmD, PhD</last_name>
    <phone>+31506314070</phone>
    <email>j.w.c.alffenaar@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart GJ Dekkers, PharmD, PhD</last_name>
      <phone>+315014071</phone>
      <email>b.g.j.dekkers@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Jan-Willem C Alffenaar, PharmD, PhD</last_name>
      <phone>+315014071</phone>
      <email>j.w.c.alffenaar@umcg.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Jan-Willem C Alffenaar</investigator_full_name>
    <investigator_title>Principal Investigator, PharmD, PhD</investigator_title>
  </responsible_party>
  <keyword>Azithromycin</keyword>
  <keyword>Immunomodulation</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Tissue degradation</keyword>
  <keyword>Tissue remodelling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

